Kazia Therapeutics Announces Sovargen Doses First Participant In Phase 1b/2a Clinical Study Of Paxalisib To Treat Epilepsies

Kazia Therapeutics Limited (NASDAQ: KZIA) announced that Sovargen Co., Ltd. has dosed the first participant in a Phase 1b/2a clinical trial of paxalisib, aimed at treating intractable epilepsy associated with focal cortical dysplasia type 2 and tuberous sclerosis complex. This milestone triggers a $2 million development payment to Kazia under their licensing agreement with Sovargen.